Keyphrases
Alzheimer's Disease
28%
Alzheimer's Disease Pathology
14%
APPswe
100%
APPswePS1dE9
100%
Cellular Level
14%
Chimeric Mice
14%
Cognitive Decline
14%
Cognitive Function
14%
Cyclic Adenosine Monophosphate (cAMP)
28%
Disease-associated Microglia
14%
Early Intervention
14%
Exon 9
14%
Filopodia Formation
14%
In Vitro Inhibition
14%
Long-range Inhibition
14%
Mental Resilience
100%
Microglia
28%
Microglia Phenotype
14%
Microglial Activation
28%
Phosphodiesterase-4 (PDE4)
100%
Presenilin
14%
Prion Protein
14%
Prodromal Phase
14%
Promising Treatment
14%
Spatial Memory
14%
Swedish mutation
14%
Synapse Loss
14%
Synaptic Dysfunction
14%
Treatment Strategy
14%
Working Memory
14%
INIS
control
14%
cyclic adenosine monophosphate
28%
diseases
14%
exons
14%
humans
28%
in vitro
14%
in vivo
14%
inhibition
100%
interventions
14%
levels
14%
losses
28%
mice
100%
mutations
14%
nervous system diseases
42%
pathology
14%
phenotype
14%
phosphodiesterases
100%
promoters
14%
proteins
14%
regulations
14%
sweden
14%
Medicine and Dentistry
Alzheimer's Disease
50%
Cognition
16%
Cyclic AMP
16%
Cyclic AMP Phosphodiesterase
16%
Disease
16%
Early Intervention
16%
Exon
16%
Filopodia
16%
In Vitro
16%
Microglia
66%
Phosphodiesterase
100%
Prion Protein
16%
Promoter Protein
16%
Spatial Memory
16%
Swedish Mutation
16%
Synapse
16%
Working Memory
16%
Neuroscience
Alzheimer's Disease
50%
Cognitive Function
16%
Cyclic Adenosine Monophosphate
16%
Cyclic AMP Phosphodiesterase
16%
Exon
16%
In Vitro
16%
In Vivo
16%
Microglia
66%
Phosphodiesterase
100%
Prion Protein
16%
Promoter Region
16%
Spatial Memory
16%
Synapse
16%
Working Memory
16%